Os therapies to provide ost-her2 recurrent, fully resected, pulmonary metastatic osteosarcoma fda end of phase 2 meeting update on tuesday, september 2, 2025

New york, new york--(newsfile corp. - august 27, 2025) - os therapies inc. (nyse american: ostx) ("os therapies" or "the company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will provide stakeholders with a detailed update regarding the company's highly constructive august 27, 2025 end of phase 2 meeting with the us food & drug administration ("fda") discussing the regulatory path forward towards approval for ost-her2 in recurrent, fully resected, pulmonary metastatic osteosarcoma on tuesday, september 2, 2025. about os therapies os therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma (os) and other solid tumors.
OST Ratings Summary
OST Quant Ranking